Gilead reports 23% placebo-adjusted remission for colitis pill in Phase 2
The 200 milligram daily dose of the pill, emvistegrast, was taken for 12 weeks by patients with moderate to severe ulcerative colitis.
The 200 milligram daily dose of the pill, emvistegrast, was taken for 12 weeks by patients with moderate to severe ulcerative colitis.